Key Points
[1/2]A box of Ozempic, a semaglutide injection drug used for treating type 2 diabetes and made by Novo Nordisk, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023..
FRANKFURT, Nov 15 (Reuters) - The head of German drug regulator BfArM is considering an export ban on Novo Nordisk's (NOVOb.CO) diabetes drug Ozempic, which is in high demand for its weight-loss benefits, to prevent a worsened supply shortage...
Ozempic is approved to treat type 2 diabetes but has increasingly been prescribed "off-label" to treat weight loss because it has the same active ingredient as Novo's hugely popular but scarce anti-obesity drug Wegovy...
In a statement on its website, BfArM reiterated a call for physicians to only prescribe drugs from the class of GLP-1 receptor agonists, which include Ozempic and Eli Lilly's (LLY.N).
You might be interested in
Belgium seizes fake weight-loss drugs containing insulin
30, Oct, 23Belgium’s drug regulator said it had seized counterfeit versions of semaglutide, the active ingredient in Novo Nordisk's (NOVOb.CO) popular obesity drug Wegovy, in which the injector pens contained insulin.
Swedish regulator asks doctors not to prescribe diabetes drugs for weight loss
11, Dec, 23Sweden's drugs agency on Monday asked doctors to hold off on prescribing diabetes drugs for the treatment of obesity, pointing to signs that a spike in such usage has left diabetics short of medication.
US diabetes patients face delays as insurers tighten Ozempic coverage
12, Dec, 23Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as U.S. insurers implement restrictions designed to deter doctors from prescribing the medication for weight loss.
Your Company Doesn’t Want You to Take Ozempic for Weight Loss. Here’s Why.
22, May, 23Many employers’ health plans are trying to restrict access to the pricey drug and alternatives like Wegovy
Has a 'magical' weight loss drug finally arrived? Hopes soar with US firm's never-before-seen results
29, Jun, 23Patients who got a weekly injection of the experimental anti-obesity drug retatrutide lost up to 24 per cent of their body weight in 48 weeks, show phase-2 trials published this week.
Belgium bans use of Ozempic for weight loss until summer
14, Nov, 23Belgium has decided to temporarily ban the use of Novo Nordisk's (NOVOb.CO) diabetes drug Ozempic as a weight loss treatment amid a shortage of the medicine, according to a royal decree published in the country's Official Gazette on Tuesday.
Novo Nordisk's diabetes drug Ozempic back in supply in US after months of shortage
18, Mar, 23Novo Nordisk's best-selling diabetes treatment drug Ozempic is back on the shelves in the United States after months of shortage, the U.S. Food and Drug Administration (FDA) website showed on Friday.
EMA says no evidence GLP-1 drugs like Ozempic linked to thyroid cancer
27, Oct, 23The European Medicines Agency (EMA) on Friday said its safety panel did not find a causal link between popular GLP-1 drugs such as Novo Nordisk's (NOVOb.CO) Ozempic and thyroid cancer after a months-long review.
Weight-loss drugs in spotlight as pharma services firms rush to snap up business
27, Oct, 23Soaring demand for obesity drugs was in the spotlight at the world's largest trade show for the pharmaceutical services industry this week, as it fuels a boom for firms that fill and assemble the self-injection pens.
EU watchdog seeks more data from GLP-1 drugmakers on suicidal thoughts
03, Dec, 23The EU's drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Novo Nordisk's (NOVOb.CO) popular therapies Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them.